Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.26 USD | +0.71% | +3.65% | +17.03% |
Apr. 29 | MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment | MT |
Apr. 29 | MannKind Gets FDA Clearance for Clofazimine IND Application | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.03% | 1.15B | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+1.95% | 22.18B | |
-16.67% | 21.2B | |
-9.00% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- MNKD Stock
- News MannKind Corporation
- Earnings Flash (MNKD) MANNKIND Reports Q3 Revenue $51.3M, vs. Street Est of $50.7M